2,6-Dichloro-3-fluoroacetophenone | CAS:290835-85-7

We serve 2,6-Dichloro-3-fluoroacetophenone CAS:290835-85-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2,6-Dichloro-3-fluoroacetophenone

Chemical Name:2,6-Dichloro-3-fluoroacetophenone
CAS.NO:290835-85-7
Synonyms:2,6-Dichloro-3-fluoroacetophenone
1-(2,6-dichloro-3-fluorophenyl)ethanone
2,6-Dichloro-3-Fluro Acetophenone
 
Physical and Chemical Properties:
Density 1.4±0.1 g/cm3
Boiling Point 216.0±35.0 °C at 760 mmHg
Molecular Formula C8H5Cl2FO
Molecular Weight 207.029
Flash Point 84.4±25.9 °C
Vapour Pressure 0.1±0.4 mmHg at 25°C
Index of Refraction 1.530
 
Specification:
Appearance:Colorless transparent liquid
Assay:≥98.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like 2,6-Dichloro-3-fluoroacetophenone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,6-Dichloro-3-Fluro Acetophenone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,6-Dichloro-3-Fluro Acetophenone Use and application,2,6-Dichloro-3-Fluro Acetophenone technical grade,usp/ep/jp grade.


Related News: Delta moved the date up after the US State Department warned that people should not travel to China due to concerns about the spread of coronavirus, which was first discovered in Wuhan, Hubei province, in December.m-cresol manufacturer An analysis of the top 20 global companies by R&D spend for 2018 shows that companies with expensive late-stage pipeline drugs are spending significant proportions of their annual revenue on R&D.3-Isopropoxyaniline supplier An analysis of the top 20 global companies by R&D spend for 2018 shows that companies with expensive late-stage pipeline drugs are spending significant proportions of their annual revenue on R&D.1,2-Bis(triethoxysilyl)ethane vendor ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment’s chemistry, manufacturing and controls process, but not its safety.ViiV, in which Pfizer and Shionogi have small stakes, said it received a so-called complete response letter (CRL) from the FDA in which the regulator questioned the treatment’s chemistry, manufacturing and controls process, but not its safety.